S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Cogent Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.10 (+1.19 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $8.49
50-Day Range
MA: $10.50
52-Week Range
Now: $8.49
Volume458,809 shs
Average Volume1.22 million shs
Market Capitalization$360.56 million
P/E RatioN/A
Dividend YieldN/A
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Cogent Biosciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:UMRX
Phone(617) 945-5576
Year FoundedN/A



Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share


Net Income$-31,830,000.00


Market Cap$360.56 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.92 out of 5 stars

Medical Sector

1058th out of 1,958 stocks

Pharmaceutical Preparations Industry

489th out of 772 stocks

Analyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cogent Biosciences (NASDAQ:UMRX) Frequently Asked Questions

Is Cogent Biosciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cogent Biosciences stock.
View analyst ratings for Cogent Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Cogent Biosciences?

Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The company earned $0.53 million during the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%.
View Cogent Biosciences' earnings history

What price target have analysts set for UMRX?

4 brokers have issued 1 year price targets for Cogent Biosciences' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Cogent Biosciences' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 52.9%.
View analysts' price targets for Cogent Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Cogent Biosciences' key executives?

Cogent Biosciences' management team includes the following people:
  • Andrew R. Robbins, President, Chief Executive Officer & Director
  • Geoffrey Hodge, Chief Technical Officer & Senior VP-Operations
  • John L. Green, Chief Financial & Accounting Officer
  • Jessica Sachs, Chief Medical Officer
  • Greg Motz, Head-Research

Who are some of Cogent Biosciences' key competitors?

What other stocks do shareholders of Cogent Biosciences own?

When did Cogent Biosciences IPO?

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "UMRX."

What is Cogent Biosciences' stock price today?

One share of UMRX stock can currently be purchased for approximately $8.49.

How much money does Cogent Biosciences make?

Cogent Biosciences has a market capitalization of $360.56 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Cogent Biosciences have?

Cogent Biosciences employs 72 workers across the globe.

What is Cogent Biosciences' official website?

The official website for Cogent Biosciences is www.unumrx.com.

Where are Cogent Biosciences' headquarters?

Cogent Biosciences is headquartered at 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at (617) 945-5576 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.